These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31249206)

  • 1. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
    Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
    Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
    Mossong J; Putz L; Schneider F
    Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
    Gohil DJ; Kothari ST; Chaudhari AB; Gunale BK; Kulkarni PS; Deshmukh RA; Chowdhary AS
    Viral Immunol; 2016 Apr; 29(3):159-63. PubMed ID: 26910764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
    Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
    Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
    Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
    An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.
    Poethko-Müller C; Mankertz A
    PLoS One; 2012; 7(8):e42867. PubMed ID: 22880124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
    Plans P; de Ory F; Campins M; Álvarez E; Payà T; Guisasola E; Compte C; Vellbé K; Sánchez C; Lozano MJ; Aran I; Bonmatí A; Carreras R; Jané M; Cabero L
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1161-71. PubMed ID: 25666082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
    BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination.
    Mahamud A; Masunu-Faleafaga Y; Walls L; Williams N; Garcia P; Teshale E; Williams R; Dulski T; Bellini WJ; Kutty PK
    Vaccine; 2013 Aug; 31(36):3683-7. PubMed ID: 23770334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
    Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y
    J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory.
    Ghafoori F; Mokhtari-Azad T; Foroushani AR; Farahmand M; Shadab A; Salimi V
    BMC Infect Dis; 2024 Jul; 24(1):696. PubMed ID: 38997625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.